Try our beta test site
4 studies found for:    lymphoma OR CLL | Daratumumab
Show Display Options
Rank Status Study
1 Not yet recruiting A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type
Condition: Lymphoma
Intervention: Drug: Daratumumab
2 Recruiting An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Conditions: Lymphoma, Mantle-Cell;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular
Intervention: Drug: Daratumumab
3 Recruiting An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab, With or Without Pomalidomide and Dexamethasone, in Patients With Multiple Myeloma
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Biological: Lirilumab;   Biological: Daratumumab;   Drug: Pomalidomide;   Drug: Dexamethasone
4 Recruiting Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia
Condition: T-cell Type Acute Leukemia-Precursor T-lymphoblastic Lymphoma/Leukaemia
Interventions: Drug: Isatuximab SAR650984;   Drug: dexamethasone;   Drug: acetaminophen;   Drug: ranitidine;   Drug: diphenhydramine

Study has passed its completion date and status has not been verified in more than two years.